Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback